RT Journal Article
SR Electronic
T1 Ganciclovir concentrations in the cerebral extracellular space after valganciclovir treatment; a case study
JF BMJ Case Reports
FD BMJ Publishing Group Ltd
SP bcr2014207694
DO 10.1136/bcr-2014-207694
VO 2015
A1 Peredo, Inti
A1 Helldén, Anders
A1 Wolmer-Solberg, Nina
A1 Pohanka, Anton
A1 Stragliotto, Giuseppe
A1 Rahbar, Afsar
A1 Ståhle, Lars
A1 Bellander, Bo-Michael
A1 Söderberg-Nauclér, Cecilia
YR 2015
UL http://casereports.bmj.com/content/2015/bcr-2014-207694.abstract
AB Nearly all glioblastomas (GBMs), brain tumours with very poor prognosis, are infected with human cytomegalovirus (CMV). The anti-CMV drug valganciclovir (VGCV) has shown promise as a treatment option for patients with GBM, but its penetration into the central nervous system (CNS) is unknown. Here we describe a patient with GMB receiving VGCV in whom an intracerebral microdialysis catheter was implanted and ganciclovir (GCV) concentrations in brain extracellular fluid (BECF) and serum were monitored. GCV was rapidly absorbed. Cmax values (at 3 h) in serum and BECF were 19.6 and 10.2 µmol/L, T½ values were 3.2 and 4.5 h, and plasma and BECF AUC0−∞ values were 90.7 and 75.9 µmol h/L, respectively. Thus, VGCV treatment results in significant intracerebral levels of GCV that may be sufficient for therapeutic effects. Further studies of this drug in patients with GBM are warranted.